Interleukin-15 in autoimmunity

Copyright © 2020 Elsevier Ltd. All rights reserved..

Interleukin-15 (IL-15) is a member of the IL-2 family of cytokines, which use receptor complexes containing the common gamma (γc) chain for signaling. IL-15 plays important roles in innate and adaptative immune responses and is implicated in the pathogenesis of several immune diseases. The IL-15 receptor consists of 3 subunits namely, the ligand-binding IL-15Rα chain, the β chain (also used by IL-2) and the γc chain. IL-15 uses a unique signaling pathway whereby IL-15 associates with IL-15Rα during biosynthesis, and this complex is 'trans-presented' to responder cells that expresses the IL-2/15Rβγc receptor complex. IL-15 is subject to post-transcriptional and post-translational regulation, and evidence also suggests that IL-15 cis-signaling can occur under certain conditions. IL-15 has been implicated in the pathology of various autoimmune diseases such as rheumatoid arthritis, autoimmune diabetes, inflammatory bowel disease, coeliac disease and psoriasis. Studies with pre-clinical models have shown the beneficial effects of targeting IL-15 signaling in autoimmunity. Unlike therapies targeting other cytokines, anti-IL-15 therapies have not yet been successful in humans. We discuss the complexities of IL-15 signaling in autoimmunity and explore potential immunotherapeutic approaches to target the IL-15 signaling pathway.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:136

Enthalten in:

Cytokine - 136(2020) vom: 30. Dez., Seite 155258

Sprache:

Englisch

Beteiligte Personen:

Allard-Chamard, Hugues [VerfasserIn]
Mishra, Hemant K [VerfasserIn]
Nandi, Madhuparna [VerfasserIn]
Mayhue, Marian [VerfasserIn]
Menendez, Alfredo [VerfasserIn]
Ilangumaran, Subburaj [VerfasserIn]
Ramanathan, Sheela [VerfasserIn]

Links:

Volltext

Themen:

Autoimmunity
IL-15
IL15 protein, human
Immunotherapy
Interleukin-15
Journal Article
Research Support, Non-U.S. Gov't
Review
Rheumatoid arthritis
Type 1 diabetes

Anmerkungen:

Date Completed 26.11.2021

Date Revised 26.11.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.cyto.2020.155258

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM314913858